【Aims】Peripheral vertigo has been reported to result from oxidative stress (OS) or 2 autonomic nervous dysfunction. Recently, heart rate variability (HRV) has been used to 3 evaluate autonomic nervous activity (ANA). Parasympathetic nervous dysfunction is 4 associated with peripheral vertigo; however, the relationships among vertigo, OS, and 5 ANA have not been investigated. The aim of this study was to elucidate the changes in 6 OS and ANA in vertigo patients compared with healthy volunteers (HVs). 【Methods】 7 OS was assessed by evaluating biological antioxidant potential (BAP) and reactive 8 oxygen metabolites (dROM), and HRV was measured to evaluate ANA. Thirty-four 9 patients who complained of peripheral vertigo and were treated in our emergency 10 department between January and August 2011 were enrolled in study 1. OS and HRV 11
collected serum samples were divided into to 2 tubes of at least 2 mL each; these 1 samples were rapidly frozen at −80°C. These samples were defrosted within 72 h and 2 BAP and dROM were measured using Free Radical Analytical System 4 (FRAS4 TM , 3
Health & Diagnostics Limited Co., Parma, Italy). BAP reflected the blood level of 4 antioxidant substances. The BAP test uses a colored solution containing ferric (Fe 3+ ) 5 ions bound to a special chromogenic substrate that changes color when the Fe 3+ ions are 6 reduced to ferrous ions (Fe 2+ ). Then, 10 μL of the serum sample was added to the 7 cuvette. After incubating for 5 min at 37°C, absorbance at 505 nm was recorded. The 8 dROM test reflected the blood level of reactive oxygen metabolites, particularly that of 9 hydroperoxides, which are markers and amplifiers of free radical-induced oxidative 10 damage. In this test, the ROM level is proportional to the intensity of red coloration. In 11 brief, 20 μL of blood and 1 mL of buffered solution were mixed in a cuvette, and 10 μL 12 of the chromogenic substrate was added to the cuvette. After mixing and centrifugation 13 for 60 s, the cuvette was incubated in a thermostatic block for 5 min at 37°C. Thereafter, 14 absorbance at 505 nm was recorded. The results were expressed as U.CARR. 15
HRV was assessed using a sphygmograph (TAS9 TM Pulse Analyzer Plus, YKC 16
Corporation, Tokyo, Japan) attached to the left forefinger while the patients lay silently 17 on a bed in the supine position with their eyes closed. It was recorded for 2.5 min and 18 the frequency domain information was analyzed automatically with a fast Fourier 19
Transformation. The technical details of HRV analysis have been presented in detail 20 previously [8] [9] [10] . In brief, the power spectral components of the R-R interval between 21 0.04-0.15 Hz were considered LF components and those between 0.15-0.40 Hz were 22 considered HF components. The heart rate data was sampled immediately after each 23 heart beat and was transferred to a personal computer and analyzed with suppliedsoftware. The heart rate values were averaged, and the LF and HF power values were 1 calculated by integrating each frequency band every 2.5 min; these measurements were 2 then subjected to further analysis 10 . Patients with arrhythmias were excluded from HRV 3 analysis, because HRV could not be measured correctly with an irregular heart rhythm. 4
5

Study protocol and evaluation 6
Using these OS (BAP, dROM) and HRV measurements, we established 2 study 7 protocols. In the first study (study 1), OS and HRV were compared between vertigo 8 patients treated at our ED between January to August 2011 and HVs (N = 23). In the 9 second study (study 2), OS and HRV in vertigo patients were compared before and after 10 the conventional treatment of vertigo. This treatment included a 2-h infusion of Sordem 11
3A
TM (200 mL, Ohtsuka, Tokyo, Japan) mixed with adenosine triphosphate (ATP) 12 disodium hydrate (40 mg) and 8.4% sodium bicarbonate (20 mL). If the patient 13 complained of nausea, 10 mg of metoclopramide was injected through the intravenous 14 line. Whole blood samples (10 mL) were collected immediately after visiting the ED for 15 the "before treatment" data and then collected immediately after the 2-h infusion for the 16 "after treatment" data. Patients included in the second study were treated in our ED 17 between January and August 2012. 18
19
Statistics 20
Data are expressed as mean ± standard deviation (SD). Welch's t-test was used 21
for comparisons of groups in study 1, and the paired t-test was used in study 2. 22
Statistical analyses were performed using GraphPad Prism 5 (GraphPad Software, La 
Patient background 4
The patients selected for studies 1 and 2 are shown in Figure 1 . In study 1, BAP 5 and dROM were measured in 34 patients (age: 64 ± 15 years, 12 males and 22 females), 6
and HRV in 24 patients (age: 56 ± 17 years, 9 males and 15 females). Twenty-three HVs 7
(age: 36 ± 11 years, 15 males and 8 females) were included in this study as a control 8 group. Ten patients were excluded because of arrhythmia. In study 2, HRV was 9 measured in 41 patients (age: 59 ± 14 years, 15 males and 26 females) before and after 10 the treatment of vertigo, whereas BAP and dROM were evaluated in 18 patients (age: 11 65 ± 15 years, 6 males and 12 females). Twenty-three patients were excluded because 12 they did not give consent (Fig. 1) . 13
14
Oxidative stress in vertigo patients 15
We measured BAP, dROM, and the BAP/dROM ratio in vertigo patients 16 compared with HVs (Fig. 2) . The BAP/dROM ratio was evaluated to investigate the 17 balance of OS. dROM were significantly higher in vertigo patients than in HVs (HVs: that superoxide and oxygen metabolites were higher in vertigo patients than in HVs. 22
Sympathetic nervous activity (LF/HF), parasympathetic nervous activity (HF), 1 and the sympathetic/parasympathetic nervous activity ratio, which is reflective of ANA 2 balance (LF/HF 2 , defined as the ANA ratio), were assessed (Fig. 3) . All data were 3 logarithm transformed and compared with the values of HVs. There was no significant 4 difference in sympathetic nervous activity between HVs and vertigo patients (HVs: 1.02 5 ± 0.23, Pt: 1.14 ± 0.30, Fig. 3A) . However, parasympathetic nervous activity in vertigo 6 patients was significantly suppressed (HVs: 5.27 ± 1.00, Pt: 4.13 ± 2.34, Fig. 3B , p < 7 0.05) and the ANA ratio was significantly elevated compared with HVs (HVs: 0.20 ± 8 0.08, Pt: 0.47 ± 0.51, Fig. 3C , p < 0.05). These results suggest that ANA balance was 9 disturbed in vertigo patients. 10 11
Effect of treatment on oxidative stress in vertigo patients 12
The changes in BAP, dROM, and the BAP/dROM ratio before and after the 2-h 13 treatment of vertigo are shown in In our study, we quantitatively evaluated physiological stress in vertigo patients 8 by measuring OS and ANA. As an OS biomarker, dROM were significantly higher in 9 vertigo patients than in HVs (Fig. 2B) . Parasympathetic nervous activity, as quantified 10 by HF of HRV, was significantly suppressed in vertigo patients compared with HVs (Fig.  11   3B) . 12 Similar to our findings, some studies have reported an elevation of OS in 13 vertigo patients 3, 4, 11 . The production of dROM results from several mechanisms, 14 including oxidative phosphorylation in the mitochondria as a product of normal cellular 15 aerobic metabolism 12, 13 . Thus, dROM can be produced by the major process from which 16 the body derives energy 13 . The balance between dROM production and activation of the 17 antioxidant defense system is crucial in human physiology and the control of cellular 18 , which cause the overproduction of OS. Therefore, it is 21 difficult to determine the source of production of dROM. It is possible that OS promotes 22 vasculitis of the vertebrae and endolymphatic hydrops in vertigo patients 3, 4 . 23
Measurement of OS could evaluate not only the severity of vertigo but also the cause ofvertigo. 1 Previous studies 7, 8, 11, 16 have reported significant parasympathetic nervous 2 hypofunction in vertigo patients, which is similar to the findings of our study (Fig. 3B) . 3
It was considered that the suppression of parasympathetic activity and the relative 4 hyperfunction of sympathetic activity in vertigo patients influenced the vertebrobasilar 5 arterial system. These pathophysiological mechanisms may produce laterality of 6 peripheral vestibular function, thus resulting in vertigo 9 . Therefore, one possible 7 mechanism of vertigo is change in blood flow and pressure in the vertebrobasilar artery 8 and cochleovestibular organs. . After treatment, dROM decreased significantly 15 (Fig. 4B) and ANA balance was also attenuated (Fig. 5C) . Possibly, adding antioxidants 16 to our medication protocol would enhance the effect of the conventional treatment. Our 17 management of these patients now includes bedside monitoring of HRV and 18 measurement of oxidative activity, which is very useful and can be measured repeatedly. 19
Our study has some limitations. First, patients with arrhythmia were excluded 20 because accurate HRV analysis could not be performed in these patients. However, 21 some patients complaining of vertigo have synchronizing paroxysmal arrhythmia. 22
Second, the age and sex of HVs and vertigo patients were different. Vertigo patients 23
were older and included a higher number of females. This background difference couldhave induced a bias. Further studies are necessary using age-and sex-matched HVs. 1 2 3
Conclusion 4
We quantitatively evaluated physiological stress in vertigo patients using OS 5 and HRV. We found that OS was significantly higher and parasympathetic activity was 6 significantly suppressed in vertigo patients. After the conventional treatment of vertigo, 7 dROM was reduced and ANA balance was improved. Bedside monitoring of OS and 8 HRV may be useful for the diagnosis of vertigo and evaluation of the effect of 9 treatment. 10 11 12
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